Title : TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.

Pub. Date : 2015 Apr

PMID : 25156865






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 TP53mut patients had lower response rates (22% compared with 76% CR in TP53 wild-type (wt) patients, P < 0.001) and reduced OS (2 and 16 months, respectively, P < 0.001). Chromium tumor protein p53 Homo sapiens
2 TP53mut patients had lower response rates (22% compared with 76% CR in TP53 wild-type (wt) patients, P < 0.001) and reduced OS (2 and 16 months, respectively, P < 0.001). Chromium tumor protein p53 Homo sapiens